ORHub, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ORHub, Inc. (OTC: ORHB) develops and provides cloud-based surgical software platforms focused on real-time data analytics, resource management, and healthcare fintech solutions for hospitals, ambulatory surgery centers, medical device vendors, physicians, and patients in the United States. The company offers a suite of modular SaaS applications including Surgical Resource Management (SRM) for preoperative planning, intraoperative collaboration, and postoperative analytics; Surgical Spotlight for cloud-based performance metrics and profitability insights; digital payment processing to accelerate vendor reimbursements and reduce case-to-cash timelines; and regenerative therapeutics through its PUR Biologics subsidiary, featuring bone graft substitutes, autologous cell-based products for osteoarthritis, degenerative disc disease, cartilage regeneration, and pain mitigation in orthopedic categories such as hip, knee, and spine. These solutions capture surgical data from electronic health records and web-enabled devices to enable anatomical depictions, predictive analytics, implant accountability, and AI-driven efficiencies across the perioperative process. Founded prior to its 2016 OTC listing and headquartered at 9830 South 51st Street in Phoenix, Arizona, with operational presence in Irvine, California, ORHub serves the health information services sector by integrating with partners like Zimmer Biomet, Hoag Hospital, BPB Medica, and Precision Spine. Recent developments include a 2022 acquisition of PUR Biologics to enter the biologics and global medical device markets valued at over $445 billion; a name transition announcement to HippoFi reflecting its fintech evolution across SRM, digital payments, regenerative therapeutics, and AI segments; expansion of PUR Biologics' distributor network to 239 in the ortho-spine market as of 2023; and a strategic partnership with Precision Spine to leverage sales channels for accelerated growth, while maintaining OTC Pink trading under ORHB with ambitions for OTCQB and Nasdaq uplisting.
Hippofi Welcomes Scott Bauccio as New Head of Sales for Pur Biologics
HippoFi Ships International Orders and Expects Sales to Exceed $20 Million in the New Year
HippoFi Continues to Deliver Sales Growth Adding 14 Major Healthcare Facilities
Dr. Gail Naughton, World-Renowned Authority in the Multibillion-Dollar Regenerative Medicine Market, Joins HippoFi as the Head of Regenerative Therapeutics and Commercialization
International Sales Win for PUR Biologics
PUR Biologics Secures Innovative Medical Patent with Strong Financial Upside
HippoFi Announces Strategic Alliance to Lead Spinal Biologics Innovation
HippoFi To Announce Strategic Alliance With Orthopedic Industry Leader
HippoFi is Finalizing Definitive Agreements to Join Forces with Industry Giant to Revolutionize the Spinal Biologic Market
HippoFi Anticipates a New Strategic Partnership as the Company Prepares to Launch PURmarrow 360, a Patented Stem Cell Harvesting Device